Hints and tips:
Related Special Reports
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
...The payday would mark the second time Mr Hantson has cashed in by selling a pharma company he runs, following Shire’s $32bn takeover of US drugmaker Baxalta in 2016....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
...Takeda Pharmaceuticals, which closed a £46bn deal for Irish drugmaker Shire last year, is in talks to sell its domestic over-the counter medicine business for several billion dollars to reduce its debt....
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
...That compared with $107bn on 177 deals in 2019 — heavily boosted by pharma group Takeda’s completion of its £46bn acquisition of Ireland’s Shire — and $24bn on 152 deals in 2018, according to Dealogic....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...After having its own deal to move to Ireland — through a 2014 takeover of Shire — blocked by policy changes from the Obama administration, the Chicago-based company has looked elsewhere....
...The overall costs on the deal rival the near $1bn that Japanese pharmaceutical group Takeda spent on its purchase of Shire last year, although it is dwarfed by the roughly $2bn of expenses and fees paid...
...Christophe Weber is racing to win backing for Japan’s largest-ever outbound takeover, which would catapult the Osaka-based drugmaker into the ranks of the world’s biggest pharmaceutical companies....
...Allergan, one of the most prolific dealmakers in the pharmaceutical sector, said on Thursday it was considering a return to the acquisition trail....
...If completed, it would rank as one of the industry’s biggest, and mark a significant moment in the evolution of Japan Inc as a global dealmaker....
...Allergan said it had not yet made an offer to Shire....
...She worked as a janitorial supervisor at C&W client Lonza, a Swiss pharmaceuticals group, which has a production facility in Portsmouth, New Hampshire....
...Earlier this week, Shire agreed to sell its oncology business for $2.4bn in cash to Servier, a French pharmaceutical group....
...Japanese pharma group Takeda weighs bid for Shire In the latest sign of the revived appetite for dealmaking among drugmakers, Japan’s Takeda Pharmaceutical indicated its interest in buying Shire, the UK-listed...
...The two critiqued Allergan’s “arbitrary debt reduction target” as it pursues M&A, including its consideration of a bid for Shire, which it subsequently abandoned....
...The company, which recently ruled itself out of a bidding war for Irish drugmaker Shire, generated adjusted earnings of $3.74 per share on revenues of $3.67bn....
...The latest acquisition contributes to a record year for Japanese outbound deals, led by Takeda Pharmaceutical’s £46bn agreement to buy Irish drugmaker Shire in April....
...In 2014, investors, including Paulson & Co, suffered paper losses after US pharmaceuticals group AbbVie walked away from its £32bn deal to buy Shire....
...assembled its £46bn bid for Shire....
...Last week, Japan’s Takeda Pharmaceutical reached a preliminary agreement to buy Irish drugmaker Shire for about £46bn in a deal that bankers predicted was a portent of things to come....
International Edition